Overview

Safety and Tolerability Study of XXB750 in Heart Failure Participants With Reduced Ejection Fraction (HFrEF)

Status:
Not yet recruiting
Trial end date:
2022-10-21
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized, sponsor open-label, participant and investigator blinded, placebo-controlled, single dose study to investigate the safety and tolerability of a single subcutaneous dose of XXB750 in HFrEF.
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals